Table 2 Descriptive analysis and the results of bivariable MEML models for efficacy
From: Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study
Patient’s clinical features | Descriptive | SVR (%) | P-value | |||||
|---|---|---|---|---|---|---|---|---|
Fail | SVR12 | TOT | estimate | 95% CI | ||||
Total | 347 | 4780 | 5127 | 93.41% | 92.48% | 94.34% | NA | |
Treatment group | group B | 182 | 1488 | 1670 | 89.50% | 87.66% | 91.34% | < 0.001 |
group A | 72 | 1891 | 1963 | 96.48% | 95.58% | 97.38% | ||
group C | 84 | 1357 | 1441 | 94.43% | 93.09% | 95.77% | ||
NA | 9 | 44 | 53 | – | – | – | – | |
Cirrhosis | no | 81 | 1937 | 2018 | 95.99% | 95.13% | 96.84% | < 0.001 |
CHILD A | 194 | 2606 | 2800 | 93.07% | 92.13% | 94.01% | ||
CHILD B/C | 72 | 237 | 309 | 76.70% | 71.99% | 81.41% | ||
NA | 0 | 0 | 0 | – | – | – | – | |
Sex | female | 85 | 1848 | 1933 | 95.67% | 94.70% | 96.65% | < 0.001 |
male | 262 | 2932 | 3191 | 91.98% | 90.77% | 93.18% | ||
NA | 0 | 0 | 0 | – | – | – | – | |
Age | ≤59 | 194 | 2474 | 2668 | 92.96% | 91.73% | 94.19% | 0.141 |
≥60 | 150 | 2281 | 2431 | 93.98% | 92.88% | 95.08% | ||
NA | 3 | 25 | 28 | – | – | – | – | |
BMI | BMI < 30 | 288 | 4080 | 4368 | 93.57% | 92.62% | 94.53% | 0.176 |
BMI ≥ 30 | 59 | 683 | 742 | 92.25% | 90.21% | 94.29% | ||
NA | 0 | 17 | 17 | – | – | – | – | |
HCV RNA a T0 (Log10 UI/L) | ≤ 5.99 | 206 | 2455 | 2661 | 92.39% | 91.15% | 93.62% | 0.005 |
≥6.00 | 140 | 2306 | 2446 | 94.34% | 93.33% | 95.35% | ||
NA | 1 | 19 | 20 | – | – | – | – | |
Genotype | 1a | 81 | 1102 | 1183 | 93.30% | 91.73% | 94.88% | 0.011 |
1b | 119 | 1866 | 1985 | 94.09% | 92.95% | 95.24% | ||
2 | 39 | 679 | 718 | 94.64% | 92.94% | 96.33% | ||
3 | 77 | 728 | 805 | 90.64% | 88.43% | 92.84% | ||
4 | 30 | 401 | 431 | 93.18% | 90.72% | 95.63% | ||
NA | 1 | 4 | 5 | – | – | – | – | |
Previous therapy | naive | 191 | 2599 | 2790 | 93.49% | 92.27% | 94.71% | 0.758 |
experienced | 132 | 1876 | 2008 | 93.71% | 92.41% | 95.01% | ||
NA | 24 | 305 | 329 | – | – | – | – | |
OLT | no | 330 | 4662 | 4992 | 93.53% | 92.63% | 94.42% | 0.009 |
yes | 17 | 118 | 135 | 87.75% | 82.11% | 93.39% | ||
NA | 0 | 0 | 0 | – | – | – | – | |
HIV | HIV neg. | 285 | 4082 | 4367 | 93.65% | 92.67% | 94.62% | 0.014 |
HIV pos. | 55 | 527 | 582 | 90.89% | 88.28% | 93.50% | ||
NA | 7 | 171 | 178 | – | – | – | – | |
HCC | No | 324 | 4626 | 4950 | 93.70% | 92.73% | 94.67% | < 0.001 |
yes | 20 | 94 | 114 | 82.80% | 75.73% | 89.87% | ||
NA | 3 | 60 | 63 | – | – | – | – | |